Stay updated on Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial
Sign up to get notified when there's something new on the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page.

Latest updates to the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page
- CheckyesterdayChange DetectedAdded a government funding lapse notice. Updated the site to revision v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check8 days agoChange DetectedGlossary visibility was added and footer metadata was updated to include 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', with capitalization changes in related labels.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. This is a minor version update with no impact on study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check43 days agoChange DetectedAdded a dedicated Locations section with regional site listings (Arizona, California, Florida, Tennessee, Texas, Alberta, and Quebec) and replaced the previous location blocks. The HHS Vulnerability Disclosure link was removed in this update.SummaryDifference0.8%

- Check65 days agoChange DetectedRevision: v3.3.2 was implemented, replacing the previous v3.3.1. This is a minor maintenance update that does not modify any study details, eligibility criteria, or results displayed on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check72 days agoChange DetectedThe Publications section text was updated from 'about the study results' to 'about the results of the study,' and a new 'Revision: v3.3.1' label was added.SummaryDifference0.1%

Stay in the know with updates to Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vicriviroc and Pembrolizumab in MSS CRC Clinical Trial page.